Cell Line Development Market by Product 2025 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cell Line Development Market
Cell Line Development Market: By Product (Equipment, Media and Reagents), By Source (mammalian, insect), By Type (Primary cells, Hybridomass), By Application (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) & By Region - Forecast (2017- 2022)
Report Code : HCR 0434
Updated Date: 13 March, 2017  

  • Report Description
  • Table of Contents
  • Customization Options
Cell line construction or Cell line development acts as a key factor in reducing the production costs of biopharmaceuticals while producing a high yield of product. Development and selection of cell lines compatible with production requirements can lead to significant time savings at later stages of biopharmaceuticals production. Rapid growth and technological advancement in pharmaceutical industry is expected to remain key growth driver for cell line development market during the period of study. 

This report identifies the global cell line development market size in for the year 2015-2017, and forecast of the same for year 2022. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global cell line development market.

Cell Line Development Market

Geographically North America dominated the global cell line development market owing to technological advancement, higher investment in R&D activities by healthcare and pharmaceutical industry. North America was followed by Europe and Asia-Pacific as the second and third largest markets for cell line development. However Asia-Pacific is expected to remain the fastest growing market during the period of study driven by rapidly expanding and increasing presence of global pharmaceutical and healthcare giants in the major economies such as India and China in the region. 

This report segments global cell line development market on the basis of product, source, type, application, end user and regional market as follows:
  • On the basis of products this report on global cell line development market is segmented as follows, covering all major products in the cell line development as follows: Products, Media, Reagents and Sera 
  • This report on global cell line development also covers in detail various sources of cell line development, some of the major sources covered in the report are mammalian, amphibian and insect
  • This report on global cell line development also covers in detail types of cell line development, some of the major types covered in the report are cloud based, Primary Cell Lines, Continuous Cell Lines, Hybridomas, Recombinant Cell Lines
  • This report on global cell line development also covers in detail various applications of cell line development, some of the major applications covered in the report are bioproduction, Tissue Engineering & Regenerative Medicine, toxicity Testing, Research, Drug Discovery
  • This report on cell line development has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets in each of the region

Sample Companies Profiled in this Report are:
  • GE Healthcare (Division of General Electric Company) 
  • American Type Culture Collection (ATCC) 
  • Corning, Inc. 
  • European Collection of Cell Cultures (ECACC) 
  • Lonza Group AG
  • 30+.
1. Cell Line Development Market – Overview
2. Executive Summary 
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Cell Line Development Market– Forces
   4.1. Drivers
      4.1.1. Technological advancement in pharmaceutical industry
      4.1.2. Rising vaccine production
   4.2. Restraints
      4.2.1. High capital requirement
      4.2.2. Development of stable and authenticate cell line
   4.3. Opportunities
      4.3.1. Increasing Risk of Pandemics and Communicable Diseases 
      4.3.2. Low Income Countries to Create Opportunities for the Cell Line Market
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cell Line Development Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life cycle Analysis
   5.5. Suppliers & Distributors
6. Cell Line Development Market, By Product
   6.1. Cell Line Development Market, Products
      6.1.1. Biosafety Cabinets 
      6.1.2. Cell Counters & Viability Analysis Systems 
      6.1.3. Incubators 
      6.1.4. Centrifuges 
      6.1.5. Bioreactors 
      6.1.6. Storage Equipment
      6.1.7. Automation Systems 
      6.1.8. Microscopes 
      6.1.9. Filtration Systems 
      6.1.10. Other Equipment
   6.2. Cell Line Development Market, Media & Reagents
      6.2.1. Sera
      6.2.2. Media
      6.2.3. Reagents
7. Cell Line Development Market, By Source
   7.1. Mammalian 
   7.2. Insect 
   7.3. Amphibian
8. Cell Line Development Market, By Type
   8.1. Primary Cell Lines 
   8.2. Continuous Cell Lines 
   8.3. Hybridomas 
   8.4. Recombinant Cell Lines
9. Cell Line Development Market, By Application
   9.1. Bioproduction
   9.2. Tissue Engineering & Regenerative Medicine 
   9.3. Toxicity Testing 
   9.4. Research 
   9.5. Drug Discovery
10. Cell Line Development Market, By Geography
   10.1. Europe
      10.1.1. Germany
      10.1.2. France
      10.1.3. Italy
      10.1.4. Spain
      10.1.5. Russia
      10.1.6. U.K.
      10.1.7. Rest of Europe
   10.2. Asia Pacific
      10.2.1. China
      10.2.2. India
      10.2.3. Japan
      10.2.4. South Korea
      10.2.5. Rest of Asia-Pacific
   10.3. North America 
      10.3.1. U.S.
      10.3.2. Canada
      10.3.3. Mexico
   10.4. Rest of the World (RoW)
      10.4.1. Middle East
      10.4.2. South America
      10.4.3. Africa
11. Cell Line Development – Market Entropy
   11.1. Expansion
   11.2. Technological Developments
   11.3. Merger & Acquisitions, and Joint Ventures
   11.4. Supply- Contract
12. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   12.1. American Type Culture Collection (ATCC) 
   12.2. Corning, Inc. 
   12.3. European Collection of Cell Cultures (ECACC) 
   12.4. GE Healthcare 
   12.5. Lonza Group AG 
   12.6. Sartorius AG 
   12.7. Selexis SA 
   12.8. Sigma-Aldrich Corporation 
   12.9. Thermo Fisher Scientific, Inc. 
   12.10. Wuxi Apptec 
*More than 30 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
13. Appendix
   13.1. Abbreviations
   13.2. Sources
   13.3. Research Methodology
   13.4. Bibiliography
   13.5. Compilation of Expert Insights
   13.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll